-----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: webmaster@www.sec.gov originator-key-asymmetric: mfgwcgyevqgbaqicaf8dsgawrwjaw2snkk9avtbzyzmr6agjlwyk3xmzv3dtinen twsm7vrzladbmyqaionwg5sdw3p6oam5d3tdezxmm7z1t+b+twidaqab mic-info: rsa-md5,rsa, cw4mxibxzxid4fzryihfzwcxbisija3tt6rehvs9bahpnj6tnvomvc4y/vl1etj0 j6b2t1om1vls6ybxisrytg== 0001144204-10-050772.txt : 20100924 0001144204-10-050772.hdr.sgml : 20100924 20100924131636 accession number:		0001144204-10-050772 conformed submission type:	sc 13d public document count:		1 filed as of date:		20100924 date as of change:		20100924 filed by:		 	company data:	 		company conformed name:			wang zhen jiang 		central index key:			0001501502 	filing values: 		form type:		sc 13d 	mail address:	 		street 1:		room 1301, 13th floor, cre building 		street 2:		303 hennessey road 		city:			wanchai, hong kong 		state:			f4 		zip:			00000 subject company:	 	company data:	 		company conformed name:			first china pharmaceutical group, inc. 		central index key:			0001432254 		standard industrial classification:	radio & tv broadcasting & communications equipment [3663] 		irs number:				743232809 		state of incorporation:			nv 		fiscal year end:			1231 	filing values: 		form type:		sc 13d 		sec act:		1934 act 		sec file number:	005-85603 		film number:		101088366 	business address:	 		street 1:		800 bellevue way 		street 2:		suite 400 		city:			bellevue 		state:			wa 		zip:			98004 		business phone:		425 646 2391 	mail address:	 		street 1:		800 bellevue way 		street 2:		suite 400 		city:			bellevue 		state:			wa 		zip:			98004 	former company:	 		former conformed name:	e dispatch inc 		date of name change:	20080414 sc 13d 1 v197012_sc13d.htm unassociated document securities and exchange commission washington, d.c. 20549 &#160; schedule 13d under the securities exchange act of 1934 &#160; &#160; first china pharmaceutical group, inc. (name of issuer) &#160; common stock, $.001 par value (title of class of securities) &#160; 31948n 109 (cusip number) &#160; zhen jiang wang c/o first china pharmaceutical group, inc. room 1301, 13 th floor cre building 303 hennessey road wanchai, hong kong (name, address, and telephone number of person authorized &#160;to receive notices and communications) &#160; with a copy to: mark c. lee, esq. greenberg traurig, llp 1201 k street, suite 1100 sacramento, california 95814 &#160; september 15, 2010 (date of event which requires filing of this statement) &#160; if the filing person has previously filed a statement on schedule 13g to report the acquisition that is the subject of this schedule 13d, and is filing this schedule because of &#167;&#167;240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o &#160; note : &#160; schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.&#160;&#160; see &#167;240.13d-7 for other parties to whom copies are to be sent. &#160; * the remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. &#160; the information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of section 18 of the securities exchange act of 1934 (&#8220;act&#8221;) or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act (however, see the notes). &#160; &#160; cusip no. 31948n 109 page 2 of 5 &#160; &#160; 1 name of reporting persons &#160; zhen jiang wang 2 check the appropriate box if a member of a group (see instructions) (a) o (b) o 3 sec use only &#160; 4 source of funds (see instructions) sc 5 check box if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e) &#160; o 6 citizenship or place of organization china number of shares beneficially owned by each reporting person with 7 sole voting power 15,000,000 8 shared voting power 0 9 sole dispositive power 15,000,000 10 shared dispositive power 0 11 aggregate amount beneficially owned by each reporting person 15,000,000 12 check box if the aggregate amount in row (11) excludes certain shares (see instructions)&#160;&#160;&#160;&#160; o 13 percent of class represented by amount in row (11) 25% 1 14 type of reporting person (see instructions) in &#160; &#160; &#160; &#160; &#160; 1 based on 60,000,000 shares outstanding on 9/15/2010. &#160; &#160; &#160; cusip no. 31948n 109 page&#160;3 of 5 &#160; &#160; item 1.&#160; security and issuer &#160; this schedule 13d relates to the shares of common stock, $.001 par value (the &#8220;common stock&#8221;), of first china pharmaceutical group, inc. (the &#8220;issuer&#8221;).&#160;&#160;the principal executive offices of the issuer are located at room 1301, 13 th floor, cre building, 303 hennessey road, wanchai, hong kong. &#160; item 2.&#160; identity and background &#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this schedule 13d is being filed by zhen jiang wang (the &#8220;reporting person&#8221;). &#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the business address of the reporting person is c/o first china pharmaceutical group, inc., room 1301, 13 th floor, cre building, 303 hennessey road, wanchai, hong kong. &#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the reporting person is the chief executive officer and a director of the issuer.&#160;&#160;the address of the issuer is room 1301, 13 th floor, cre building, 303 hennessey road, wanchai, hong kong. &#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;during the last five years the reporting person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). &#160; (e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;during the last five years the reporting person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. &#160; (f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the reporting person is a citizen of china. &#160; item 3.&#160; source and amount of funds or other consideration &#160; the reporting person acquired 15,000,000 shares (the &#8220;shares&#8221;) of the issuer&#8217;s common stock in exchange for all of the outstanding shares (the &#8220;fcpg hk shares&#8221;) of capital stock of first china pharmaceutical group limited (&#8220;fcpg hk&#8221;), pursuant to a share exchange agreement (the &#8220;agreement&#8221;), by and among the issuer, fcpg hk, kun ming xin yuan tang pharmacies co., ltd., and the reporting person.&#160;&#160;the agreement was filed with the securities and exchange commission on august 24, 2010 on a current report on form 8-k. &#160; item 4.&#160; purpose of the transaction &#160; the reporting person received the shares in exchange for the fcpg hk shares under the agreement. &#160; subject to on going evaluation, except as set forth above, the reporting person has no current plans or proposals which relate to or would result in any of the following: &#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer; &#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an extraordinary corporate transaction, such as a merger, reorganization, or liquidation, involving the issuer or any of its subsidiaries; &#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a sale or transfer of a material amount of assets of the issuer or any of its subsidiaries; &#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; &#160; (e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any material change in the present capitalization or dividend policy of the issuer; &#160; &#160; &#160; &#160; cusip no. 31948n 109 page 4 of 5 &#160; &#160; (f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any other material change in the issuer&#8217;s business or corporate structure, including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the investment company act of 1940; &#160; (g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;changes in the issuer&#8217;s charter, bylaws, or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person; &#160; (h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; &#160; (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a class of equity securities of the issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the securities exchange act of 1934, as amended; or &#160; (j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any action similar to any of those enumerated above. &#160; item 5.&#160; interest in securities of the issuer &#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the reporting person beneficially owns 15,000,000 shares of common stock, which represent 25% of the outstanding shares of common stock. &#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the reporting person has sole power to vote and sole power to dispose of 15,000,000 shares of common stock. &#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no transactions in the issuer&#8217;s common stock were effected during the past 60 days by the reporting person except as set forth in item 3 above. &#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not applicable. &#160; (e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not applicable. &#160; item 6. contracts, arrangements, understandings or relationships with respect to securities of the issuer &#160; reference is made to the transaction stated in item 3 above. &#160; item 7.&#160; material to be filed as exhibits &#160; none &#160; &#160; &#160; &#160; cusip no. 31948n 109 page 5 of 5 &#160; &#160; signature &#160; after reasonable inquiry and to the best of my knowledge and belief, i certify that the information set forth in this statement is true, complete, and correct. &#160; dated:&#160;&#160;september 15, 2010 &#160; /s/ zhen jiang wang zhen jiang wang &#160; &#160; &#160; &#160; &#160; -----end privacy-enhanced message----- 